{"entity":{"id":"nct02938299","kind":"trial","name":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","aka":[],"tldr":"A phase 3 trial of L19IL2 + L19TNF in melanoma, run by Philogen S.p.A., active and no longer recruiting.","summary":"Neoadjuvant L19IL2/L19TNF- Pivotal Study is a phase 3 interventional study registered as NCT02938299 by Philogen S.p.A., with 214 participants enrolled, started 2016-07-01 and due to reach its primary completion in 2024-10. Interventions recorded: L19IL2 + L19TNF and Surgery.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02938299","url":"https://clinicaltrials.gov/study/NCT02938299"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","stage-iii-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["philogen-s-p-a"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct02938299-ann-oncol-2025","paper-nct02938299-j-clin-oncol-2026-update"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02938299","phase":"3","setting":"A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients","sponsor":"Philogen S.p.A.","started":"2016-07-01","startedType":"actual","enrolled":214,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02938299/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"company":[{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/"}],"paper":[{"id":"paper-nct02938299-j-clin-oncol-2026-update","kind":"paper","name":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial","route":"/key-papers/paper-nct02938299-j-clin-oncol-2026-update/"},{"id":"paper-nct02938299-ann-oncol-2025","kind":"paper","name":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","route":"/key-papers/paper-nct02938299-ann-oncol-2025/"}]}}